The Cutaneous Connection

We recently caught up with Peter Lio, MD, a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, at the 2024 Society for Pediatric Dermatology Annual Meeting. Lio presented a session on changing the disease course in pediatric atopic dermatitis, alongside Amy Paller, MD. We'll dive into the highlights of their talk, the role of disease progression, and the exciting pipeline ahead.

In today’s episode, Drs Vikash Oza, MD, and James Treat, MD, delve into the topic, “Does Food Trigger Eczema?” Oza, an associate professor of dermatology and pediatrics and the director of pediatric dermatology at NYU in New York City, and Treat, a professor of clinical pediatrics and dermatology at the Perelman School of Medicine and an affiliate of the Children’s Hospital of Philadelphia, participated in 1 of 3 “Great Debates in Peds Derm” at the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada. The duo shared insights from their debate and pearls for clinicians related to allergy and eczema. 

In today’s episode, Albert Yan, MD, FAAP, FAAD, research director at the Children's Hospital of Philadelphia, professor at the Perelman School of Medicine, and executive at Inner Archways LLC, discusses pearls and insights from his lecture presented at the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada. Yan spoke on artificial intelligence and ChatGPT and the balance of positive yet harmful potential of AI chatbots in medicine. 

James Song, MD, FAAD, chief medical officer and director of clinical research at Frontier Dermatology in Seattle, Washington, delves into the complexities and advancements in treating atopic dermatitis (AD). Song highlights the challenges of transitioning patients from topical to systemic therapies, emphasizing the need for timely conversations and patient comfort. He discusses the efficacy and rapid response of oral JAK inhibitors compared to biologics, while addressing safety concerns and the necessity for blood monitoring. Song also explores patient-specific factors in treatment choices, the importance of systemic therapy for moderate to severe cases, and the promise of emerging biologics targeting IL-31 and OX40 pathways. This episode is a comprehensive guide for dermatology clinicians navigating the evolving landscape of AD treatments. 

In today’s episode, Nanette Silverberg reviews the key highlights from her vitiligo sessions at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, also known this year as RAVE. Dr. Silverberg is the chief of pediatric dermatology for the Mount Sinai Health System and site director of pediatric and adolescent dermatology at Mount Sinai West and Mount Sinai Beth Israel in New York, as well as the conference chair of the vitiligo portion of RAVE. At the conference, Dr. Silverberg presented “Topical Therapeutics for Vitiligo” and “Excellence in Vitiligo Clinical Practice.” Today, Dr. Silverberg shares the top takeaways from her sessions that clinicians can utilize in their practice. 

Bradley Burnam, the founder and CEO of Turn Therapeutics, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of Hexagen technology and its potential in eczema, onychomycosis, and more.

Brian Kim, MD, had an unexpected attendee at one of his AAD sessions and delves into what's new, what's now, and what's next in atopic dermatitis management.

Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut and Dermatology Times Editorial Advisory Board Member, caught up with us at the 2024 American Academy of Dermatology Meeting to decode new atopic dermatitis treatment data and how that translates to personalized options for patients.

Raj Chovatiya, MD, PhD, gives a sneak peek of what to expect in atopic dermatitis education at the 2024 American Academy of Dermatology (AAD) Meeting in San Diego, California March 8-12. Since the last meeting, the AAD has released new guidelines to treat the condition. 

Nanette Silverberg, MD, clinical professor of pediatrics and dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York, recently led the annual Revolutionizing Vitiligo (ReV) Virtual Conference. Discover what you need to say to overcome insurance coverage hangups with ruxolitinib, the importance of early intervention, and gain an overview of topical guidelines for patients of all ages with vitiligo.